TLR5 pathway activation prompted by a recombinant fusion protein vaccine containing the nontoxic domains of C. difficile toxins A and B provided immunogenicity and protective efficacy in a mouse model of CDI (15). This evidence concerns the gene TLR5 and clostridium difficile infection.